Display options
Cite
Bauckneht M, Arnaldi D, Nobili F, et al. New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases. Curr Med Chem. 2018;25(26):3105-3130doi: 10.2174/0929867324666170609080000.
Bauckneht, M., Arnaldi, D., Nobili, F., Aarsland, D., & Morbelli, S. (2018). New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases. Current medicinal chemistry, 25(26), 3105-3130. https://doi.org/10.2174/0929867324666170609080000
Bauckneht, Matteo, et al. "New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases." Current medicinal chemistry vol. 25,26 (2018): 3105-3130. doi: https://doi.org/10.2174/0929867324666170609080000
Bauckneht M, Arnaldi D, Nobili F, Aarsland D, Morbelli S. New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases. Curr Med Chem. 2018;25(26):3105-3130. doi: 10.2174/0929867324666170609080000. PMID: 28595550.
Copy Download .nbib Format: NLM
Share it on

Curr Med Chem. 2018;25(26):3105-3130. doi: 10.2174/0929867324666170609080000.

New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases.

Current medicinal chemistry

Matteo Bauckneht, Dario Arnaldi, Flavio Nobili, Dag Aarsland, Silvia Morbelli

Affiliations

  1. Nuclear Medicine Unit, Department of Health Sciences, Policlinic San Martino Hospital, 16132 Genoa, Italy.
  2. Clinical Neurology Unit, Department of Neuroscience (DINOGMI) University of Genoa and Policlinic San Martino Hospital, 16132 Genoa, Italy.
  3. King`s College of London, London, United Kingdom.
  4. Center for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway.

PMID: 28595550 DOI: 10.2174/0929867324666170609080000

Abstract

The term Lewy body diseases (LBDs) refers to a subset of neurodegenerative disorders that share the accumulation of the so-called Lewy bodies (LB) including: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and PD later characterized by the occurrence of dementia (PDD). Moreover, multiple system atrophy (MSA) and idiopatic Rem Sleeping behaviour disorders (RBD) complete the group of synucleinopathies and have also common symptoms with respect to LBDs. The clinical diagnosis of LBDs can be challenging for physicians, particularly in the early stages of disease. Given the growing number of individuals affected by these neurodegenerative disorders, early and accurate diagnosis can lead to improved clinical management of patients. For this reason, information obtained from molecular imaging biomarkers is playing an increasingly important role in this framework. The present narrative review discusses both established milestones and new evidence on the use of molecular imaging tracers already part of the clinical practice as well as available evidence on new molecular imaging approaches in PD, PDD and DLB.

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Keywords: Parkinson disease; Parkinson disease dementia; lewy bodies dementia; molecular imaging; positron emission tomography; single photon emission tomography.

MeSH terms

Publication Types